Harbin Medisan Pharmaceutical Co (SZSE:002900) Total Liabilities : ¥1,454 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Harbin Medisan Pharmaceutical Co Total Liabilities?

Harbin Medisan Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥1,454 Mil.

Harbin Medisan Pharmaceutical Co's quarterly Total Liabilities declined from Sep. 2023 (¥1,301.62 Mil) to Dec. 2023 (¥1,294.76 Mil) but then increased from Dec. 2023 (¥1,294.76 Mil) to Mar. 2024 (¥1,453.69 Mil).

Harbin Medisan Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 (¥949.04 Mil) to Dec. 2022 (¥1,225.47 Mil) and increased from Dec. 2022 (¥1,225.47 Mil) to Dec. 2023 (¥1,294.76 Mil).

Harbin Medisan Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Harbin Medisan Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Medisan Pharmaceutical Co Total Liabilities Chart

Harbin Medisan Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

820.44

712.76

949.04

1,225.47

1,294.76

Harbin Medisan Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,295.84	1,290.85	1,301.62	1,294.76	1,453.69

Harbin Medisan Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Harbin Medisan Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	845.034	+	(238.159	+	211.567
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,295

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3442.984	-	2148.224
	=	1,295

Harbin Medisan Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1151.346	+	(90.529	+	211.815
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,454

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3621.892	-	2168.203
	=	1,454

Harbin Medisan Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Harbin Medisan Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Harbin Medisan Pharmaceutical Co (SZSE:002900) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Beijing Road, Limin Development Zone, Heilongjiang Province, Harbin, CHN, 150025

Website

http://www.medisan.com.cn

Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.

Executives

Fan Qing Ji	Executives
Zhao Qing Fu	Directors, Directors, and Executives
Liang Yan Fei	Directors, executives
Yao Fa Xiang	Executives
Wang Ming Xin	Executives

Harbin Medisan Pharmaceutical Co (SZSE:002900) Headlines

No Headlines